Right-Sizing HER2-Positive Breast Cancer Treatment: New Algorithms Reshape Care Across the Disease Continuum

HER2-positive breast cancer has undergone one of the most dramatic therapeutic transformations in the history of oncology. A disease once defined by aggressive biology and poor survival has become highly curable in its early stages, and a substantial proportion of patients with metastatic disease now live beyond five years. A comprehensive new review published in Nature Reviews Clinical Oncology maps this evolution and argues that the field has entered a new phase: the challenge is no longer simply generating more effective drugs, but right-sizing therapy — matching intensity to risk, biology, response, toxicity and patient preference — across every point of the disease continuum, from tiny node-negative tumors to heavily pretreated metastatic disease.

The biological foundation of this progress lies in the ERBB2 oncogene, which encodes the HER2 receptor tyrosine kinase. Amplification of ERBB2 drives constitutive signaling through downstream pathways that promote proliferation, survival and invasion, and it was first linked to aggressive breast cancer behavior and shortened survival in landmark work published in Science in 1987. That discovery created the therapeutic target. Monoclonal antibodies such as trastuzumab and pertuzumab, which bind the extracellular domain of the receptor and block signaling and antibody-dependent cellular cytotoxicity, were followed by small-molecule tyrosine-kinase inhibitors that act intracellularly, and most recently by antibody–drug conjugates (ADCs) that couple a HER2-directed antibody to a cytotoxic payload released selectively at the tumor site.

The most consequential recent arrival is trastuzumab deruxtecan (T-DXd), an ADC with a high drug-to-antibody ratio, a cleavable linker and a membrane-permeable payload that exerts a bystander effect on neighboring tumor cells. Originally demonstrated in heavily pretreated metastatic disease, T-DXd has now been moved rapidly into earlier lines of therapy and even into the curative setting. The review highlights its emerging roles in the first-line metastatic setting — where the DESTINY-Breast09 trial showed that T-DXd plus pertuzumab outperformed the traditional taxane, trastuzumab and pertuzumab regimen — as adjuvant treatment for high-risk residual disease after neoadjuvant chemotherapy, and as a neoadjuvant option in high-risk early breast cancer, as tested in DESTINY-Breast11. Each step forward creates new opportunity but also new uncertainty about optimal sequencing, duration and retreatment.

In early-stage disease, right-sizing cuts in two directions. For patients with low-risk tumors — small, node-negative cancers — the field has successfully de-intensified therapy. The APT trial established that weekly paclitaxel plus trastuzumab delivers excellent long-term outcomes for node-negative disease, and the ATEMPT trial compared the ADC trastuzumab emtansine (T-DM1) with that regimen in stage I disease, showing comparable efficacy with a different toxicity profile. Even more minimalist approaches, such as chemotherapy-free dual HER2 blockade in selected patients, are being explored in trials like DECRESCENDO and WSG-ADAPT, supported by biomarkers such as the HER2-enriched intrinsic subtype and tumor-infiltrating lymphocytes that identify tumors most likely to respond to antibody therapy alone.

For patients with stage II–III disease, the focus has shifted to optimizing the neoadjuvant chemotherapy backbone. Anthracyclines, once standard, have been progressively dropped from many HER2-directed regimens after trials such as TRAIN-2 demonstrated comparable outcomes without them, sparing patients cardiac and secondary-leukemia risks. Carboplatin, too, is being re-evaluated: the randomized phase III neoCARHP trial showed noninferiority of taxane-based dual blockade without carboplatin, and the HELEN-006 trial found that weekly nab-paclitaxel with trastuzumab and pertuzumab matched the classic docetaxel–carboplatin doublet. These de-escalation strategies matter because long-term survival in early HER2-positive disease is now so favorable that late toxicities and quality of life weigh heavily in treatment decisions.

At the other end of the early-disease spectrum sits the patient with residual invasive disease after neoadjuvant therapy, historically the group at highest relapse risk. The KATHERINE trial established adjuvant T-DM1 as the standard for these patients, and the more recent DESTINY-Breast05 program has now pushed T-DXd into this space for high-risk residual disease, following evidence from a phase III trial reported in the New England Journal of Medicine that T-DXd improved invasive disease-free survival in this population. The review emphasizes that residual disease is heterogeneous — varying in size, nodal status, hormone receptor status and residual cancer burden — and that escalation should be risk-based rather than uniform, with genomic tools such as HER2DX and circulating tumor DNA assays under development to refine who truly needs intensification.

In metastatic disease, the algorithm is being rebuilt around two concepts: maintenance therapy and first-line intensification. After induction with a taxane plus trastuzumab and pertuzumab, patients traditionally continued dual antibody therapy alone. New maintenance options are expanding that framework. The HER2CLIMB-05 phase III trial tested tucatinib — a highly selective HER2 tyrosine-kinase inhibitor with central nervous system activity — versus placebo added to trastuzumab and pertuzumab as first-line maintenance, while for hormone receptor-positive disease the addition of the CDK4/6 inhibitor palbociclib to trastuzumab and endocrine therapy has shown benefit in advanced settings. Meanwhile, DESTINY-Breast09 has positioned continuous T-DXd plus pertuzumab as a new first-line standard, raising unresolved questions about how long such intensive therapy should continue, how to sequence subsequent lines, and whether patients with exceptional responses might eventually de-escalate.

Biomarkers are emerging as the connective tissue that could make right-sizing practical at scale. Quantitative HER2 expression measured by tissue and plasma profiling correlates with ADC activity and may predict benefit from T-DXd. The PAM50 intrinsic subtype, particularly the HER2-enriched phenotype, predicts pathological complete response to HER2-directed therapy and underpins the commercially available HER2DX genomic assay, which is now being tested prospectively in the DEFINITIVE trial. Dynamic imaging biomarkers, including FDG-PET response adapted in the PHERGain strategy, allow chemotherapy de-escalation in patients showing early metabolic response, and ultrasensitive circulating tumor DNA tracking can identify minimal residual disease and exceptional responders, informing trials such as HEROES that explore treatment withdrawal in patients with sustained deep response.

The review also confronts persistent evidence gaps and equity concerns. The optimal duration of first-line T-DXd plus pertuzumab remains unknown, as does the value of retreating with T-DXd after prior exposure, an approach being studied in the EN-SEMBLE cohort. Brain metastases remain a dominant site of failure in HER2-positive disease, and the review details how tucatinib-based regimens, T-DXd and modern stereotactic radiation strategies are reshaping central nervous system management, while noting the risk of symptomatic necrosis when ADCs are combined with brain radiotherapy. Globally, access to HER2-targeted therapies remains uneven, and real-world data reveal racial and ethnic disparities in outcomes even among patients receiving ADCs, underscoring that right-sizing must include right of access.

What emerges from this synthesis is a vision of HER2-positive breast cancer care as a continuum of calibrated decisions rather than a fixed sequence of regimens. For the low-risk patient, the goal is a cure with the least toxicity; for the high-risk residual-disease patient, intelligent escalation; for the metastatic patient, durable control with the flexibility to intensify, maintain or step down as biology dictates. The tools — ADCs, kinase inhibitors, CDK4/6 inhibitors, genomic classifiers, ctDNA and molecular imaging — are largely in hand. The task now, the authors conclude, is to deploy them with precision, powered by prospective biomarker-driven trials that convert an era of drug abundance into an era of individually right-sized cures.

Subject of Research: Risk-adapted treatment strategies for HER2-positive breast cancer across early-stage and metastatic settings

Article Title: Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum

Article References: Tarantino, P., Valenza, C., Segui, E., Lin, N. U., Prat, A., Curigliano, G., Waks, A. G., & Tolaney, S. M. (2026). Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-026-01211-5

Image Credits: AI Generated

DOI: 10.1038/s41571-026-01211-5

Keywords: HER2-positive breast cancer, trastuzumab deruxtecan, antibody-drug conjugates, de-escalation, neoadjuvant therapy, residual disease, maintenance therapy, tucatinib, palbociclib, circulating tumor DNA, HER2DX, biomarkers